Donmienne Doen Mun Leung

This inventor holds 12 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignee: Eli Lilly and Company. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Donmienne Doen Mun Leung. Retrieved from https://idiyas.com/inventor/donmienne-doen-mun-leung

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 4)

% Patents Active = 41.7

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 4.3

ph-index = 3

Forward Citations = 31(Granted Patents)

Company Filing History:

12 out of 4,517

Eli Lilly and Company

patents

Years Active: 2010-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12227538 - Glucocorticoid receptor agonists (2025-02-18),

2. 9932397 - VEGFA/Ang2 Compounds (2018-04-03),

3. 9695241 - Ang2 antibodies (2017-07-04),

4. 9580499 - VEGFR2/Ang2 compounds (2017-02-28),

5. 9416182 - Anti-TNF-anti-IL-17 bispecific antibodies (2016-08-16),

6. 9243046 - Variants of human GDNF (2016-01-26),

7. 8765129 - Anti-hepcidin antibodies and uses thereof (2014-07-01),

8. 8679497 - Anti-ferroportin 1 monoclonal antibodies and uses thereof (2014-03-25),

9. 8609817 - Anti-hepcidin-25 selective antibodies and uses thereof (2013-12-17),

10. 8329174 - Anti-hepcidin antibodies and uses thereof (2012-12-11),

11. 8183346 - Anti-ferroportin 1 monoclonal antibodies and uses thereof (2012-05-22),

12. 7820163 - Anti-hepcidin antibodies and uses thereof (2010-10-26),

Title: The Innovative Work of Inventor Donmienne Doen Mun Leung

Introduction:

Inventor Donmienne Doen Mun Leung from San Diego, CA, has made significant contributions to the field of medicine with his groundbreaking inventions. With a total of 11 patents to his name, Leung's work is focused on developing compounds and antibodies for the treatment of various diseases, including cancer and proliferative retinopathies.

Latest Patents:

Leung's latest patents include:

1. VEGFA/Ang2 Compounds: These compounds target human Vascular Endothelial Growth Factor A (VEGFA) and human Angiopoietin-2 (Ang2), with potential applications in treating angiogenic eye diseases and solid tumors like gastric, lung, and breast cancers.

2. Ang2 Antibodies: These antibodies bind to human Angiopoietin-2 (Ang2) and show promise in treating cancer, particularly in combination with VEGF pathway inhibitors for cancers driven by VEGFR2 and Ang2.

Career Highlights:

Currently affiliated with Eli Lilly and Company, Leung continues to drive innovation in the pharmaceutical industry. His work at Eli Lilly has been instrumental in developing novel therapeutics for challenging medical conditions.

Collaborations:

Leung collaborates closely with esteemed colleagues such as Ying Tang and Derrick Ryan Witcher. Together, they combine their expertise to pioneer new treatment options and improve patient outcomes in the healthcare sector.

Conclusion:

In conclusion, Inventor Donmienne Doen Mun Leung's inventive spirit and dedication to advancing medical science through his patented compounds and antibodies are commendable. His work not only benefits patients with various diseases but also inspires further research and innovation in the field.

Profile summary based on public USPTO records.